The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-25 and is reviewed periodically as new material appears.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Before recording, Parsons and Harris played a preliminary four-show mini-tour as the headline act in a June 1973 Warner Bros. Records country rock package with the New Kentucky Colonels and Country Gazette. A shared backing band included Clarence White, Pete Kleinow and Chris Ethridge. On July 15, 1973, White was killed by a drunk driver in Palmdale, California, while loading equipment in his car for a concert with the New Kentucky Colonels. At White's funeral, Parsons and Bernie Leadon performed a rendition of "Farther Along"; that evening, Parsons reportedly informed Phil Kaufman of his final wish: to be cremated in Joshua Tree National Monument.
Pakistani cuisine, rooted in the royal kitchens of 16th-century Mughal emperors, blends influences from British, Indian, Central Asian, and Middle Eastern culinary traditions. Unlike Middle Eastern fare, Pakistani dishes are heavily spiced with garlic, ginger, turmeric, chilli, and garam masala. Roti, a wheat-based flatbread, accompanies most meals, alongside curry, meat, vegetables, and lentils. Rice is also common, served plain, spiced, or in sweet dishes. Lassi, a traditional drink from the Punjab region, and black tea with milk and sugar are popular beverages enjoyed nationwide. Sohan halwa, a beloved sweet dish from southern Punjab, is savoured across Pakistan.
== Chemistry == Flunitrazepam is classed as a nitro-benzodiazepine. It is the fluorinated N-methyl derivative of nitrazepam. Other nitro-benzodiazepines include nitrazepam (the parent compound), nimetazepam (methylamino derivative) and clonazepam (2ʹ-chlorinated derivative). Flunitrazepam has a melting point of around 170 degrees Celsius.
== Biological Functions == 2,5-DKPs have been shown to play a role in interspecies bacterial quorum sensing. For example, the 2,5-DKP cyclo(Phe-Pro) has been shown to play a role in the regulation of gene expression in multiple different species of bacteria including V. fishceri, V. cholera, Lactobacillus reuteri, Staphylococcus aureus, among others.
A monopeptide has one amino acid (not alone but combined with (an)other type(s) of molecule(s)). A dipeptide has two amino acids. A tripeptide has three amino acids. A tetrapeptide has four amino acids. A pentapeptide has five amino acids. (e.g., enkephalin). A hexapeptide has six amino acids. (e.g., angiotensin IV). A heptapeptide has seven amino acids. (e.g., spinorphin). An octapeptide has eight amino acids (e.g., angiotensin II). A nonapeptide has nine amino acids (e.g., oxytocin). A decapeptide has ten amino acids (e.g., gonadotropin-releasing hormone and angiotensin I). A undecapeptide has eleven amino acids (e.g., substance P). The same words are also used to describe a group of residues in a larger polypeptide (e.g., RGD motif).
Sources: en.wikipedia.org
=== Health and death === On September 16, 1999, Barker was in Washington, D.C., to testify before Congress regarding proposed legislation that would ban captive elephants from traveling shows, such as circuses. While preparing for the presentation, Barker experienced what he called clumsiness in his right hand. Barker was admitted to George Washington University Hospital and diagnosed with a partially blocked left carotid artery. He underwent carotid endarterectomy to remove the blockage. The procedure went well enough that Barker was able to return to work within the month. Three years later, Barker had two additional health crises after taping the 30th-season finale of The Price is Right. While lying in the sun on May 30, 2002, he experienced a stroke and was hospitalized; six weeks later, on July 11, Barker underwent prostate surgery. Both hospitalizations occurred at George Washington University Hospital in Washington, D.C. and both surgeries were successful. Barker had several mild bouts with skin cancer, a result of his frequent tanning. Barker consulted a dermatologist regularly to make sure any cancers were caught and removed before they spread; they did not pose a threat to his life. During a televised interview, Barker told viewers, "I urge anyone who has spent some time in the sun, whether you're doing it now or not, go to a dermatologist once a year." On October 20, 2015, two police officers passing Barker's Los Angeles-area home saw him trip and fall on a sidewalk.
== Biological significance == Chondronectin helps keep joint tissue strong and properly supported. By helping cells attach to the surrounding framework, it supports cartilage structure, and these cells produce and repair the materials that cushion bones. To function properly, they must stay attached to collagen. This stable bond helps cartilage handle daily pressure and movement, while strong connections also help prevent the tissue from gradually breaking down over time. Joints experience less wear when these cells remain connected. Articular cartilage takes on heavy pressure every day. Special proteins help by holding the cells and tissue together, which kepp the whole structure from gradually becoming weak over time. Chondronectin is one protein that perfroms this supportive role. It helps keep the cells and fibers in the proper place. This organized layout helps the surrounding area remain balanced and also helps joints handle normal wear over time. Cartilage cells must stay attached to their base in order to survive. This bond helps tissues handle stress and remain durable over time. A protein called chondronectin helps support this important process. It is not found in the highest amounts within the joint, but its adhesive role still helps maintain normal cartilage movement and support.
Laidlaw stated that reasons behind the cancellation included the fact that headcrabs and zombies "were pretty much played out at the time", and that the fact that it had to take place chronologically prior to Half-Life 2: Episode Two was too creatively constraining. Footage of the project was shown in a 2020 documentary by media company Noclip titled The Untold History of Arkane.
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was studied by Pfizer as a potential treatment of metabolic disorders such as type 2 diabetes mellitus. Its development was terminated in 1999.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.